MILAN, Italy--(BUSINESS WIRE)--Sorin Group, (MIL:SRN), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has completed the sale, for $7 million (€5.25 million) in cash paid in installments over two and a half years, of the Angel® Whole Blood Separation System (“Angel™”) and activAT® Autologous Thrombin Processing Kit (“activAT®”) product lines to Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis. Together these products had sales of approximately $5 million (€3.75 million) in 2009.
